EW Stock Up 5.5% after 6-Day Win Streak
Edwards Lifesciences (EW) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 5.5% return. The company has gained about $2.5 Bil in value over the last 6 days, with its current market capitalization at about $46 Bil. The stock remains 5.1% above its value at the end of 2024. This compares with year-to-date returns of 13.7% for the S&P 500.
EW provides structural heart disease products, critical care, and surgical monitoring technologies, including aortic surgical valves, distributed via direct sales and independent distributors. After this rally, is EW still a buy – or is it time to lock in gains? Deep dive with Buy or Sell EW.
Comparing EW Stock Returns With The S&P 500
The following table summarizes the return for EW stock vs. the S&P 500 index over different periods, including the current streak:
- Earn 9.4% Today or Buy CROX 40% Cheaper – It’s a Win-Win
- Triggers That Could Ignite the Next Rally In Applied Materials Stock
- Palantir Technologies Stock Can Sink, Here Is How
- Cash Machine Trading Cheap – Webull Stock Set to Run?
- Momentum Meets Value: KLA Stock Could Be A Good Buy
- High Margins, 43% Discount: Buy Adobe Stock Now
| Return Period | EW | S&P 500 |
|---|---|---|
| 1D | 0.8% | 0.4% |
| 6D (Current Streak) | 5.5% | -0.1% |
| 1M (21D) | -4.4% | 3.5% |
| 3M (63D) | 0.8% | 7.9% |
| YTD 2025 | 5.1% | 13.7% |
| 2024 | -2.9% | 23.3% |
| 2023 | 2.2% | 24.2% |
| 2022 | -42.4% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has EW behaved after prior drops? See EW Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 158 S&P constituents with 3 days or more of consecutive gains and 9 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 128 | 2 |
| 4D | 19 | 3 |
| 5D | 4 | 0 |
| 6D | 5 | 2 |
| 7D or more | 2 | 2 |
| Total >=3 D | 158 | 9 |
Key Financials for Edwards Lifesciences (EW)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $5.0 Bil | $5.4 Bil |
| Operating Income | $1.5 Bil | $1.5 Bil |
| Net Income | $1.4 Bil | $4.2 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $1.4 Bil | $1.5 Bil |
| Operating Income | $409.9 Mil | $430.9 Mil |
| Net Income | $358.0 Mil | $329.8 Mil |
While EW stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.